International Exhibition on Eye Care,
Pharma Instruments & Consumables
18-19-20 August, 2018
Ophthall 2018
Exclusive Practice Development
Conference for Eye Hospitals
18-19 August, 2018

Market

India’s Ophthalmic Market Expected to Total $US1.9 Billion by 2021

Market Scope forecasts that India’s US$1.4 billion ophthalmic market is expected to grow at a compound annual rate (CAGR) of 6.5 percent a year to $US1.9 billion by 2021.

India is the second most populous country in the world and has tremendous unmet need for ophthalmic care. The country is home to 18 percent of the world’s population and approximately 30 percent of the world’s blind people. Over the past 70 years, India’s life expectancy rate has seen exceptional growth. Additional factors expected to fuel India’s ophthalmic market growth include an upsurge in dietary change-related eye diseases, growing incidence of myopia, a growing middle class, and improved access to care.

Cataract products are the largest ophthalmic surgical submarket in India. Revenues from cataract surgery in India are expected to generate nearly one-fourth of the total ophthalmic market revenues in the country. Market Scope estimates that India’s cataract market will total US$533.7 million by 2021, growing at a CAGR of 9.3 percent. Small-incision cataract surgery (SICS) is the dominant surgical procedure used to remove cataracts, accounting for over half of all cataract surgeries, but ultrasonic phacoemulsification is gaining ground. Femtosecond laser-assisted cataract surgery is just beginning to have a presence in the market. Surgeons typically use foldable IOLs and ophthalmic viscoelastic devices with either SICS or phacoemulsification.

Retinal disease is the second-leading cause of blindness in India, fueled in part by a high incidence of myopia. Retinal products are the second-largest ophthalmic revenue market in India due to the importance of anti-VEGFs in treatment. Market Scope expects India’s retinal disease market to fluctuate over the next five years as new biosimilar anti-VEGFs enter the market, but we look for revenues to remain relatively flat, totaling US$232 million in 2021.

Glaucoma, the third-largest ophthalmic submarket in India, is mainly a pharmaceutical market, and the main driver of revenue growth will be better access to glaucoma medicines. Market Scope forecasts that India’s glaucoma market will increase to US$296.5 million by 2021 at a CAGR of 10.8 percent.

Become An Exhibitor

Your gateway to reach 2,00,000 business visitors